Role of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation in Primary Systemic Amyloidosis: A Systematic Review

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 8, 2009, Pages 893-902

  Mhaskar, Rahul ^a   Kumar, Ambuj ^a,b   Behera, Madhusmita ^a   Kharfan Dabaja, Mohamed A ^a,b   Djulbegovic, Benjamin ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Amyloidosis; Autologous hematopoietic cell transplantation; Meta analysis; Systematic review

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ACUTE KIDNEY FAILURE; ADJUVANT THERAPY; AMYLOIDOSIS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG MEGADOSE; FEBRILE NEUTROPENIA; GASTROINTESTINAL DISEASE; HUMAN; INTERMETHOD COMPARISON; MEDICAL LITERATURE; MEDICAL RESEARCH; META ANALYSIS; METHODOLOGY; MORTALITY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; REVIEW; SEPSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WHOLE BODY RADIATION;

AMYLOIDOSIS; ANTINEOPLASTIC AGENTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 67649592100     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.01.022     Document Type: Review

References (37)

1. Kyle R.A., Greipp P.R., and O'Fallon W.M. Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases. Blood 68 (1986) 220-224
2. Traynor A.E., and Noga S.J. NCCN: multiple myeloma. Cancer Control 8 (2001) 78-87
3. Dhodapkar M.V., Hussein M.A., Rasmussen E., et al. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood 104 (2004) 3520-3526
4. Palladini G., Perfetti V., Obici L., et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 103 (2004) 2936-2938
5. Sanchorawala V., Wright D.G., Seldin D.C., et al. Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis. Br J Haematol 117 (2002) 886-889
6. Comenzo R.L., and Gertz M.A. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 99 (2002) 4276-4282
7. Sanchorawala V., Wright D.G., Seldin D.C., et al. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplant 33 (2004) 381-388
8. Dispenzieri A., Lacy M.Q., Kyle R.A., et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol 19 (2001) 3350-3356
9. Haynes R.B., McKibbon K.A., Wilczynski N.L., et al. Optimal search strategies for retrieving scientifically strong studies of treatment from Medline: analytical survey. BMJ 330 (2005) 1179
10. Parmar M.K., Torri V., and Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17 (1998) 2815-2834
11. Stuart A., and Ord J. Kendall's Advanced Theory of Statistics (1994), Edward Arnold, London
12. Higgins J.P.T., Thompson S.G., Deeks J.J., et al. Measuring inconsistency in meta-analyses. BMJ 327 (2003) 557-560
13. Begg C., and Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 50 (1994) 1088-1101
14. Egger M., Smith D.G., Schneider M., et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997) 629-634
15. Peters J.L., Sutton A.J., Jones D.R., et al. Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity. Stat Med 26 (2007) 4544-4562
16. Moher D., Cook D., Eastwood S., et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet 354 (1999) 1896-1900
17. Jaccard A., Moreau P., Leblond V., et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 357 (2007) 1083-1093
18. Gono T., Matsuda M., Shimojima Y., et al. VAD with or without subsequent high-dose melphalan followed by autologous stem cell support in AL amyloidosis: Japanese experience and criteria for patient selection. Amyloid 11 (2004) 245-256
19. van Gameren II, Hazenberg B.P., Jager P.L., et al. AL amyloidosis treated with induction chemotherapy with VAD followed by high-dose melphalan and autologous stem cell transplantation. Amyloid 9 (2002) 165-174
20. Blum W., Khoury H., Lin H.S., et al. Primary amyloidosis patients with significant organ dysfunction tolerate autologous transplantation after conditioning with single-dose total body irradiation alone: a feasibility study. Biol Blood Marrow Transplant 9 (2003) 397-404
21. Cohen A.D., Zhou P., Chou J., et al. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial. Br J Haematol 139 (2007) 224-233
22. Gertz M.A., Blood E., Vesole D.H., et al. A multicenter phase 2 trial of stem cell transplantation for immunoglobulin light-chain amyloidosis (E4A97): an Eastern Cooperative Oncology Group Study. Bone Marrow Transplant 34 (2004) 149-154
23. Gertz M.A., Lacy M.Q., Dispenzieri A., et al. Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med 113 (2002) 549-555
24. Gertz M.A., Lacy M.Q., Dispenzieri A., et al. Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. Haematologica 92 (2007) 1415-1418
25. Perfetti V., Siena S., Palladini G., et al. Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis. Haematologica 91 (2006) 1635-1643
26. Perz J.B., Schonland S.O., Hundemer M., et al. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single-centre prospective phase II study. Br J Haematol 127 (2004) 543-551
27. Sanchorawala V., Wright D.G., Quillen K., et al. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis. Bone Marrow Transplant 40 (2007) 557-562
28. Skinner M., Sanchorawala V., Seldin D.C., et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 140 (2004) 85-93
29. Atkins D., Best D., Briss P.A., et al. Grading quality of evidence and strength of recommendations. BMJ 328 (2004) 1490
30. Fadia A., Casserly L.F., Sanchorawala V., et al. Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL amyloidosis. Kidney Int 63 (2003) 1868-1873
31. Gillmore J.D., Hawkins P.N., and Pepys M.B. Amyloidosis: a review of recent diagnostic and therapeutic developments. Br J Haematol 99 (1997) 245-256
32. Kyle R.A., and Greipp P.R. Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo. Blood 52 (1978) 818-827
33. Kyle R.A., Gertz M.A., Greipp P.R., et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 336 (1997) 1202-1207
34. Gertz M.A., Lacy M.Q., Gastineau D.A., et al. Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). Bone Marrow Transplant 26 (2000) 963-969
35. Sanchorawala V., Wright D.G., Seldin D.C., et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 28 (2001) 637-642
36. Bradburn M.J., Deeks J.J., Berlin J.A., et al. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 26 (2007) 53-77
37. Sweeting M.J., Sutton A.J., and Lambert P.C. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 23 (2004) 1351-1375